CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. 2006

Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
Institute of Pathology, Charité Campus Mitte, Berlin, Germany.

BACKGROUND In breast cancer, the expression of CD24 represents a poorly recognised unfavourable prognostic factor. CD24 has been described to be potentially down-regulated by estrogen receptor alpha (ER). The present study was aimed at examining the predictive value of CD24 expression in tamoxifen-treated breast cancer cases. METHODS Sixty patients with primary invasive ductal breast cancers with post-operative tamoxifen treatment were enrolled in the study. Immmunohistochemical reactions were performed using monoclonal antibodies directed against CD24 and ER. RESULTS Cases demonstrating cytoplasmic-membranous expression of CD24 (CD24c-m) proved to be characterised by a significantly lower expression of ER as compared to CD24c-m-negative cases. A multivariate progression analysis based on the Cox proportional hazard model demonstrated that CD24c-m expression is an independent prognostic factor for poor overall survival. CONCLUSIONS The data from the present study suggested that CD24c-m expression is specific for tamoxifen-resistant breast cancer cases. CD24 should be subjected to comprehensive studies as a marker of resistance to tamoxifen treatment.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D051927 CD24 Antigen A GPI-linked cell adhesion protein originally identified as a heat stable antigen in mice. It mediates antigen-dependent activation and proliferation of B-CELLS. It is also involved in METASTASIS and is highly expressed in many NEOPLASMS. Antigens, CD24,CD24 Antigens,Heat-Stable Antigen CD24,Nectadrin,Antigen, CD24,CD24, Heat-Stable Antigen,Heat Stable Antigen CD24

Related Publications

Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
January 2018, Cancer cell international,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
October 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
February 1995, Lancet (London, England),
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
October 2015, Pathology, research and practice,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
August 2011, Diagnostic pathology,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
September 2004, The Journal of steroid biochemistry and molecular biology,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
December 2017, BMB reports,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
January 2018, Oncotarget,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
January 2015, OncoTargets and therapy,
Pawel Surowiak, and Verena Materna, and Piotr Paluchowski, and Rafal Matkowski, and Andrzej Wojnar, and Adam Maciejczyk, and Marek Pudelko, and Jan Kornafel, and Manfred Dietel, and Glen Kristiansen, and Hermann Lage, and Maciej Zabel
March 2014, Medical oncology (Northwood, London, England),
Copied contents to your clipboard!